Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: A prospective cohort study

Giulia Angeloni, Silvia Alberti, Enrico Romagnoli, Alberto Banzato, Marco Formichi, Umberto Cucchini, Vittorio Pengo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF). Vitamin K antagonists greatly reduce the risk of thromboembolic events, but the administration scheme before ECV is troublesome as difficulties in reaching and maintaining the target therapeutic range for 3 weeks often delay the restoration and likelihood of maintaining sinus rhythm. Low molecular weight heparins (LMWHs) do not need dose adjustment, and may be preferable in this clinical setting. In this multicentre study, the LMWH parnaparin was used at a dose of 85 anti-factor Xa U/kg b. i. d. 2 weeks before and 3 weeks after ECV of AF. In an intention to treat analysis of 102 patients, there was no systemic thromboembolism or major bleeding (0%, 95% CI 0-3. 6). Two clinically relevant non-major bleeds (2. 5%, 95% CI 0. 7-8. 8) and three minor bleeds (3. 8%, 95% CI 1. 3-10. 6) were recorded. No heparin-induced thrombocytopenia or other major adverse events were recorded. Parnaparin appears effective and safe for thromboprophylaxis of elective ECV in patients with AF.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalInternal and Emergency Medicine
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Electric Countershock
Low Molecular Weight Heparin
Atrial Fibrillation
Cohort Studies
Prospective Studies
Thromboembolism
Factor Xa
Intention to Treat Analysis
Vitamin K
Thrombocytopenia
Multicenter Studies
Heparin
Hemorrhage
parnaparin
Therapeutics

Keywords

  • Atrial fibrillation
  • Cardioembolism
  • Electrical cardioversion
  • Parnaparin

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine

Cite this

Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion : A prospective cohort study. / Angeloni, Giulia; Alberti, Silvia; Romagnoli, Enrico; Banzato, Alberto; Formichi, Marco; Cucchini, Umberto; Pengo, Vittorio.

In: Internal and Emergency Medicine, Vol. 6, No. 2, 04.2011, p. 117-123.

Research output: Contribution to journalArticle

@article{6aa055f925f44fcc9951f7895a96f5e4,
title = "Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: A prospective cohort study",
abstract = "Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF). Vitamin K antagonists greatly reduce the risk of thromboembolic events, but the administration scheme before ECV is troublesome as difficulties in reaching and maintaining the target therapeutic range for 3 weeks often delay the restoration and likelihood of maintaining sinus rhythm. Low molecular weight heparins (LMWHs) do not need dose adjustment, and may be preferable in this clinical setting. In this multicentre study, the LMWH parnaparin was used at a dose of 85 anti-factor Xa U/kg b. i. d. 2 weeks before and 3 weeks after ECV of AF. In an intention to treat analysis of 102 patients, there was no systemic thromboembolism or major bleeding (0{\%}, 95{\%} CI 0-3. 6). Two clinically relevant non-major bleeds (2. 5{\%}, 95{\%} CI 0. 7-8. 8) and three minor bleeds (3. 8{\%}, 95{\%} CI 1. 3-10. 6) were recorded. No heparin-induced thrombocytopenia or other major adverse events were recorded. Parnaparin appears effective and safe for thromboprophylaxis of elective ECV in patients with AF.",
keywords = "Atrial fibrillation, Cardioembolism, Electrical cardioversion, Parnaparin",
author = "Giulia Angeloni and Silvia Alberti and Enrico Romagnoli and Alberto Banzato and Marco Formichi and Umberto Cucchini and Vittorio Pengo",
year = "2011",
month = "4",
doi = "10.1007/s11739-010-0479-1",
language = "English",
volume = "6",
pages = "117--123",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion

T2 - A prospective cohort study

AU - Angeloni, Giulia

AU - Alberti, Silvia

AU - Romagnoli, Enrico

AU - Banzato, Alberto

AU - Formichi, Marco

AU - Cucchini, Umberto

AU - Pengo, Vittorio

PY - 2011/4

Y1 - 2011/4

N2 - Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF). Vitamin K antagonists greatly reduce the risk of thromboembolic events, but the administration scheme before ECV is troublesome as difficulties in reaching and maintaining the target therapeutic range for 3 weeks often delay the restoration and likelihood of maintaining sinus rhythm. Low molecular weight heparins (LMWHs) do not need dose adjustment, and may be preferable in this clinical setting. In this multicentre study, the LMWH parnaparin was used at a dose of 85 anti-factor Xa U/kg b. i. d. 2 weeks before and 3 weeks after ECV of AF. In an intention to treat analysis of 102 patients, there was no systemic thromboembolism or major bleeding (0%, 95% CI 0-3. 6). Two clinically relevant non-major bleeds (2. 5%, 95% CI 0. 7-8. 8) and three minor bleeds (3. 8%, 95% CI 1. 3-10. 6) were recorded. No heparin-induced thrombocytopenia or other major adverse events were recorded. Parnaparin appears effective and safe for thromboprophylaxis of elective ECV in patients with AF.

AB - Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF). Vitamin K antagonists greatly reduce the risk of thromboembolic events, but the administration scheme before ECV is troublesome as difficulties in reaching and maintaining the target therapeutic range for 3 weeks often delay the restoration and likelihood of maintaining sinus rhythm. Low molecular weight heparins (LMWHs) do not need dose adjustment, and may be preferable in this clinical setting. In this multicentre study, the LMWH parnaparin was used at a dose of 85 anti-factor Xa U/kg b. i. d. 2 weeks before and 3 weeks after ECV of AF. In an intention to treat analysis of 102 patients, there was no systemic thromboembolism or major bleeding (0%, 95% CI 0-3. 6). Two clinically relevant non-major bleeds (2. 5%, 95% CI 0. 7-8. 8) and three minor bleeds (3. 8%, 95% CI 1. 3-10. 6) were recorded. No heparin-induced thrombocytopenia or other major adverse events were recorded. Parnaparin appears effective and safe for thromboprophylaxis of elective ECV in patients with AF.

KW - Atrial fibrillation

KW - Cardioembolism

KW - Electrical cardioversion

KW - Parnaparin

UR - http://www.scopus.com/inward/record.url?scp=79953025433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953025433&partnerID=8YFLogxK

U2 - 10.1007/s11739-010-0479-1

DO - 10.1007/s11739-010-0479-1

M3 - Article

C2 - 21082292

AN - SCOPUS:79953025433

VL - 6

SP - 117

EP - 123

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 2

ER -